Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

759 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Switching from boosted PIs to dolutegravir in HIV-infected patients with high cardiovascular risk: 48 week effects on subclinical cardiovascular disease.
Gonzalez-Cordon A, Assoumou L, Camafort M, Domenech M, Guaraldi G, Domingo P, Rusconi S, Raffi F, Katlama C, Masia M, Bernardino JI, Saumoy M, Pozniak A, Gatell JM, Martinez E; NEAT022 Study Group. Gonzalez-Cordon A, et al. Among authors: domingo p. J Antimicrob Chemother. 2020 Nov 1;75(11):3334-3343. doi: 10.1093/jac/dkaa292. J Antimicrob Chemother. 2020. PMID: 32737482 Clinical Trial.
Twice-weekly maintenance therapy with sulfadiazine-pyrimethamine to prevent recurrent toxoplasmic encephalitis in patients with AIDS. Spanish Toxoplasmosis Study Group.
Podzamczer D, Miró JM, Bolao F, Gatell JM, Cosín J, Sirera G, Domingo P, Laguna F, Santamaría J, Verdejo J. Podzamczer D, et al. Among authors: domingo p. Ann Intern Med. 1995 Aug 1;123(3):175-80. doi: 10.7326/0003-4819-123-3-199508010-00003. Ann Intern Med. 1995. PMID: 7598298 Clinical Trial.
Thrice-weekly sulfadiazine-pyrimethamine for maintenance therapy of toxoplasmic encephalitis in HIV-infected patients. Spanish Toxoplasmosis Study Group.
Podzamczer D, Miró JM, Ferrer E, Gatell JM, Ramón JM, Ribera E, Sirera G, Cruceta A, Knobel H, Domingo P, Polo R, Leyes M, Cosin J, Fariñas MC, Arrizabalaga J, Martínez-Lacasa J, Gudiol F. Podzamczer D, et al. Among authors: domingo p. Eur J Clin Microbiol Infect Dis. 2000 Feb;19(2):89-95. doi: 10.1007/s100960050436. Eur J Clin Microbiol Infect Dis. 2000. PMID: 10746493 Clinical Trial.
Clinical utility of HIV-1 genotyping and expert advice: the Havana trial.
Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, González J, Domingo P, Boucher C, Rey-Joly C, Clotet B; Havana Study Group. Tural C, et al. Among authors: domingo p. AIDS. 2002 Jan 25;16(2):209-18. doi: 10.1097/00002030-200201250-00010. AIDS. 2002. PMID: 11807305 Clinical Trial.
Substitution of nevirapine, efavirenz, or abacavir for protease inhibitors in patients with human immunodeficiency virus infection.
Martínez E, Arnaiz JA, Podzamczer D, Dalmau D, Ribera E, Domingo P, Knobel H, Riera M, Pedrol E, Force L, Llibre JM, Segura F, Richart C, Cortés C, Javaloyas M, Aranda M, Cruceta A, de Lazzari E, Gatell JM; Nevirapine, Efavirenz, and Abacavir (NEFA) Study Team. Martínez E, et al. Among authors: domingo p. N Engl J Med. 2003 Sep 11;349(11):1036-46. doi: 10.1056/NEJMoa021589. N Engl J Med. 2003. PMID: 12968087 Free article. Clinical Trial.
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
Barrios A, Rendón A, Negredo E, Barreiro P, Garcia-Benayas T, Labarga P, Santos J, Domingo P, Sánchez-Conde M, Maida I, Martín-Carbonero L, Núñez M, Blanco F, Clotet B, Sambeat MA, Gil P, Gonzalez-Lahoz J, Cooper D, Soriano V. Barrios A, et al. Among authors: domingo p. AIDS. 2005 Mar 24;19(6):569-75. doi: 10.1097/01.aids.0000163933.14649.93. AIDS. 2005. PMID: 15802975 Clinical Trial.
759 results